Lumasiran

Oxlumo 189 mg/ml, oplossing voor injectie

Oplossing voor injectieNetherlandsAuthorisedAuthorised 19 Nov 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

OxlumoEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Lumasiran

Oxlumo 189 mg/ml, oplossing voor injectie

Oplossing voor injectieNetherlandsAuthorisedAuthorised 19 Nov 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

OxlumoEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

OxlumoUnited States · 94.5MG BASE/0.5ML · solution · Alnylam Pharms INC

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim · Added 8 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lumasiran
Dosage form: Oplossing voor injectie
Route: Subcutaan gebruik
Register: Netherlands (CBG-MEB)
Status: Authorised
Status in the register: Ingeschreven
Authorised: 19 Nov 2020
Registration: EU/1/20/1496
Marketing authorisation holder: Alnylam Netherlands B.V.
ATC code: A16AX18
Group: Alimentary tract and metabolism
Procedure: EU centralised
Supply: Uitsluitend recept
EMA product number: EMEA/H/C/005040
EU number: EU/1/20/1496